1. Home
  2. VRAX vs IMCC Comparison

VRAX vs IMCC Comparison

Compare VRAX & IMCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRAX
  • IMCC
  • Stock Information
  • Founded
  • VRAX 2013
  • IMCC 1980
  • Country
  • VRAX United Kingdom
  • IMCC Israel
  • Employees
  • VRAX N/A
  • IMCC N/A
  • Industry
  • VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • IMCC Medicinal Chemicals and Botanical Products
  • Sector
  • VRAX Health Care
  • IMCC Health Care
  • Exchange
  • VRAX Nasdaq
  • IMCC Nasdaq
  • Market Cap
  • VRAX 7.3M
  • IMCC 7.5M
  • IPO Year
  • VRAX 2022
  • IMCC N/A
  • Fundamental
  • Price
  • VRAX $1.63
  • IMCC $2.23
  • Analyst Decision
  • VRAX
  • IMCC
  • Analyst Count
  • VRAX 0
  • IMCC 0
  • Target Price
  • VRAX N/A
  • IMCC N/A
  • AVG Volume (30 Days)
  • VRAX 253.3K
  • IMCC 16.3K
  • Earning Date
  • VRAX 02-05-2025
  • IMCC 03-27-2025
  • Dividend Yield
  • VRAX N/A
  • IMCC N/A
  • EPS Growth
  • VRAX N/A
  • IMCC N/A
  • EPS
  • VRAX N/A
  • IMCC N/A
  • Revenue
  • VRAX $84,872.00
  • IMCC $38,042,859.00
  • Revenue This Year
  • VRAX $5,169.18
  • IMCC $22.59
  • Revenue Next Year
  • VRAX $66.97
  • IMCC $32.86
  • P/E Ratio
  • VRAX N/A
  • IMCC N/A
  • Revenue Growth
  • VRAX 7.03
  • IMCC N/A
  • 52 Week Low
  • VRAX $0.60
  • IMCC $1.50
  • 52 Week High
  • VRAX $9.00
  • IMCC $8.10
  • Technical
  • Relative Strength Index (RSI)
  • VRAX 38.98
  • IMCC 53.35
  • Support Level
  • VRAX $1.58
  • IMCC $2.05
  • Resistance Level
  • VRAX $2.29
  • IMCC $2.60
  • Average True Range (ATR)
  • VRAX 0.22
  • IMCC 0.21
  • MACD
  • VRAX -0.04
  • IMCC 0.02
  • Stochastic Oscillator
  • VRAX 11.77
  • IMCC 58.31

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

About IMCC IM Cannabis Corp.

IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.

Share on Social Networks: